RESUMEN
Human herpesvirus-6A (HHV-6A) is rarer than HHV-6B in many infant populations. However, they are similarly prevalent as germline, chromosomally integrated genomes (ciHHV-6A/B). This integrated form affects 0.1-1â% of the human population, where potentially virus gene expression could be in every cell, although virus relationships and health effects are not clear. In a Czech/German patient cohort ciHHV-6A was more common and diverse than ciHHV-6B. Quantitative PCR, nucleotide sequencing and telomeric integration site amplification characterized ciHHV-6 in 44 German myocarditis/cardiomyopathy and Czech malignancy/inflammatory disease (MI) patients plus donors. Comparisons were made to sequences from global virus reference strains, and blood DNA from childhood-infections from Zambia (HHV-6A mainly) and Japan (HHV-6B). The MI cohort were 86â% (18/21) ciHHV-6A, the cardiac cohort 65â% (13/20) ciHHV-6B, suggesting different disease links. Reactivation was supported by findings of 1) recombination between ciHHV-6A and HHV-6B genes in 20â% (4/21) of the MI cohort; 2) expression in a patient subset, of early/late transcripts from the inflammatory mediator genes chemokine receptor U51 and chemokine U83, both identical to ciHHV-6A DNA sequences; and 3) superinfection shown by deep sequencing identifying minor virus-variants only in ciHHV-6A, which expressed transcripts, indicating virus infection reactivates latent ciHHV-6A. Half the MI cohort had more than two copies per cell, median 5.2, indicative of reactivation. Remarkably, the integrated genomes encoded the secreted-active form of virus chemokines, rare in virus from childhood-infections. This shows integrated virus genomes can contribute new human genes with links to inflammatory pathology and supports ciHHV-6A reactivation as a source for emergent infection.
Asunto(s)
Cromosomas Humanos/virología , Células Germinativas/virología , Herpesvirus Humano 6/genética , Infecciones por Roseolovirus/virología , Estudios de Cohortes , Citocinas/análisis , República Checa , Alemania , Humanos , Lactante , Datos de Secuencia Molecular , Análisis de Secuencia de ADN , Proteínas Virales/análisis , Activación ViralRESUMEN
AIMS: Improvement of clinical diagnostics of idiopathic giant cell myocarditis (IGCM) and cardiac sarcoidosis (CS), two frequently fatal human myocardial diseases. Currently, IGCM and CS are diagnosed based on differential patterns of inflammatory cell infiltration and non-caseating granulomas in histological sections of endomyocardial biopsies (EMBs), after heart explantation or postmortem. We report on a method for improved differential diagnosis by myocardial gene expression profiling in EMBs. METHODS AND RESULTS: We examined gene expression profiles in EMBs from 10 patients with histopathologically proven IGCM, 10 with CS, 18 with active myocarditis (MCA), and 80 inflammation-free control subjects by quantitative RT-QPCR. We identified distinct differential profiles that allowed a clear discrimination of tissues harbouring giant cells (IGCS, CS) from those with MCA or inflammation-free controls. The expression levels of genes coding for cytokines or chemokines (CCL20, IFNB1, IL6, IL17D; P < 0.05), cellular receptors (ADIPOR2, CCR5, CCR6, TLR4, TLR8; P < 0.05), and proteins involved in the mitochondrial energy metabolism (CPT1, CYB, DHODH; P < 0.05) were deregulated in 2- to 300-fold, respectively. Bioinformatic analyses and correlation of the gene expression data with immunohistochemical findings provided novel information regarding the differential cellular and molecular pathomechanisms in IGCM, CS, and MCA. CONCLUSION: Myocardial gene expression profiling is a reliable method to predict the presence of multinuclear giant cells in the myocardium, even without a direct histological proof, in single small EMB sections, and thus to reduce the risk of sampling errors. This profiling also facilitates the discrimination between IGCM and CS, as two different clinical entities that require immediate and tailored differential therapy.
Asunto(s)
Cardiomiopatías/diagnóstico , Perfilación de la Expresión Génica/métodos , Sarcoidosis/diagnóstico , ADN Complementario/metabolismo , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Miocarditis/diagnóstico , Estudios RetrospectivosRESUMEN
Recent studies have detected erythrovirus genomes in the hearts of cardiomyopathy and cardiac transplant patients. Assessment of the functional status of viruses may provide clinically important information beyond detection of the viral genomes. Here, we report transcriptional activation of cardiotropic erythrovirus to be associated with strongly altered myocardial gene expression in a distinct subgroup of cardiomyopathy patients. Endomyocardial biopsies (EMBs) from 415 consecutive cardiac erythrovirus (B19V)-positive patients with clinically suspected cardiomyopathy were screened for virus-encoded VP1/VP2 mRNA indicating transcriptional activation of the virus, and correlated with cardiac host gene expression patterns in transcriptionally active versus latent infections, and in virus-free control hearts. Transcriptional activity was detected in baseline biopsies of only 66/415 patients (15.9 %) harbouring erythrovirus. At the molecular level, significant differences between cardiac B19V-positive patients with transcriptionally active versus latent virus were revealed by expression profiling of EMBs. Importantly, latent B19V infection was indistinguishable from controls. Genes involved encode proteins of antiviral immune response, B19V receptor complex, and mitochondrial energy metabolism. Thus, functional mapping of erythrovirus allows definition of a subgroup of B19V-infected cardiomyopathy patients characterized by virus-encoded VP1/VP2 transcripts and anomalous host myocardial transcriptomes. Cardiac B19V reactivation from latency, as reported here for the first time, is a key factor required for erythrovirus to induce altered cardiac gene expression in a subgroup of cardiomyopathy patients. Virus genome detection is insufficient to assess pathogenic potential, but additional transcriptional mapping should be incorporated into future pathogenetic and therapeutic studies both in cardiology and transplantation medicine.
Asunto(s)
Cardiomiopatías/genética , Cardiomiopatías/virología , Infecciones por Parvoviridae/virología , Transcriptoma , Cardiomiopatías/complicaciones , ADN Viral/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Parvoviridae/complicaciones , Infecciones por Parvoviridae/genética , Parvovirus B19 Humano/genética , Reacción en Cadena de la Polimerasa de Transcriptasa InversaAsunto(s)
Infarto Encefálico , Fracturas Óseas , Miocarditis , Accidentes , Infarto Encefálico/diagnóstico , Infarto Encefálico/tratamiento farmacológico , Infarto Encefálico/etiología , Electrocardiografía , Fracturas Óseas/complicaciones , Humanos , Motocicletas , Miocarditis/complicaciones , Miocarditis/diagnóstico , Miocarditis/tratamiento farmacológico , Miocarditis/etiología , Tibia/lesiones , Resultado del TratamientoRESUMEN
Parvovirus B19 is a frequent virus detected in endomyocardial biopsies of patients with clinically suspected myocarditis or dilated cardiomyopathy (DCM). Viruses often cause a more symptomatic disease with increased tissue injury if they become reactivated. A disease-specific differential expression of microRNAs (miRNAs) has been described in the regulation of replicating viruses. Analyzing patients with latent and reactivated B19V infection, we found 29 differentially regulated miRNAs and, in order to test whether predicted genes are differentially expressed, selected mRNAs were tested by TaqMan-QPCR.
Asunto(s)
Cardiomiopatías/genética , Cardiomiopatías/virología , Marcadores Genéticos/genética , MicroARNs/genética , Infecciones por Parvoviridae/genética , Infecciones por Parvoviridae/virología , Parvovirus B19 Humano/aislamiento & purificación , Cardiomiopatías/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Parvoviridae/diagnósticoRESUMEN
We have established a fast PCR-based micro flow-through process consisting of a helical constructed tube reactor. By this approach we can detect transcripts of measles and human papilloma virus (HPV) by continuous flow allowing for reverse transcription (RT) and amplification of cDNA. The micro reaction system consisted of two columnar reactors for thermostating the different reaction zones of the RT process and the amplification. The PCR reactor was built by asymmetric heating sections thus realizing different residence times and optimal conditions for denaturation, annealing and elongation. The system concept is based on low electrical power consumption (50-120 W) and is suited for portable diagnostic applications. The samples were applied in form of micro fluidic segments with single volumes between 65 and 130 nL injected into an inert carrier liquid inside a Teflon FEP tube with an inner diameter of 0.5 mm. Optimal amplification for template lengths of 292 bp (lambda-DNA), 127 bp (measles virus) and 95 bp (HPV) was achieved by maximal cycle times of 75 s.
Asunto(s)
Bacteriófago lambda/genética , Reactores Biológicos , Papillomavirus Humano 16/genética , Sarampión/genética , Reacción en Cadena de la Polimerasa/instrumentación , Bacteriófago lambda/patogenicidad , Línea Celular Tumoral , Diseño de Equipo , Femenino , Papillomavirus Humano 16/patogenicidad , Humanos , Técnicas de Amplificación de Ácido Nucleico , Reacción en Cadena de la Polimerasa/métodos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/instrumentación , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Temperatura , Factores de Tiempo , Transcripción GenéticaRESUMEN
OBJECTIVES: This report focuses on the design and methods of the 3-centre clinical study of the Transregional Collaborative Research Centre 'Inflammatory Cardiomyopathy--Molecular Pathogenesis and Therapy', which aims to establish a comprehensive research registry on the diagnostics, therapy and disease outcomes of patients with inflammatory cardiomyopathy (CMi). The study goals are to investigate specific disease sub-entities and to develop standardised strategies for diagnostics and treatment. METHODS: All consecutive patients with clinically suspected CMi, post-myocarditic cardiomyopathy and acute myocarditis are included in the research registry. Cardiopulmonary functional tests, clinical and patient data are obtained at baseline and subsequent readmission appointments and are linked to allow for prospective follow-up. Co-morbidities, quality of life, health- related behaviour and sociodemographic variables are ascertained using uniform self-administered questionnaires. PRESENT STATUS: By May 2008, 2,061 cases had been included in the research registry (1,300 data-sets completed). At registration, 335 patients were diagnosed with CMi. The mean age was 50 +/- 13 years and the mean ejection fraction was 39.9 +/- 15.8%. CONCLUSIONS: The broad range of the acquired molecular-biological, histological, immunohistological, clinical and patient data makes this the most comprehensive research registry on patients with CMi to date.
Asunto(s)
Cardiomiopatías , Miocarditis , Enfermedad Aguda , Adulto , Anciano , Cardiomegalia/epidemiología , Cardiomiopatías/diagnóstico , Cardiomiopatías/epidemiología , Cardiomiopatías/terapia , Comorbilidad , Conducta Cooperativa , Femenino , Estudios de Seguimiento , Enfermedades Genéticas Congénitas/epidemiología , Alemania , Conductas Relacionadas con la Salud , Humanos , Infecciones/epidemiología , Masculino , Persona de Mediana Edad , Miocarditis/diagnóstico , Miocarditis/epidemiología , Miocarditis/terapia , Pronóstico , Calidad de Vida , Sistema de Registros , Factores de Riesgo , Factores SocioeconómicosRESUMEN
The clinical phenotype of human dilated cardiomyopathy (DCM) encompasses a broad spectrum of etiologically distinct disorders. As targeting of etiology-related pathogenic pathways may be more efficient than current standard heart failure treatment, we obtained the genomic expression profile of a DCM subtype characterized by cardiac inflammation to identify possible new therapeutic targets in humans. In this inflammatory cardiomyopathy (DCMi), a distinctive cardiac expression pattern not described in any previous study of cardiac disorders was observed. Two significantly altered gene networks of particular interest and possible interdependence centered around the cysteine-rich angiogenic inducer 61 (CYR61) and adiponectin (APN) gene. CYR61 overexpression, as in human DCMi hearts in situ, was similarly induced by inflammatory cytokines in vascular endothelial cells in vitro. APN was strongly downregulated in DCMi hearts and completely abolished cytokine-dependent CYR61 induction in vitro. Dysbalance between the CYR61 and APN networks may play a pathogenic role in DCMi and contain novel therapeutic targets. Multiple immune cell-associated genes were also deregulated (e.g., chemokine ligand 14, interleukin-17D, nuclear factors of activated T cells). In contrast to previous investigations in patients with advanced or end-stage DCM where etiology-related pathomechanisms are overwhelmed by unspecific processes, the deregulations detected in this study occurred at a far less severe and most probably fully reversible disease stage.
Asunto(s)
Cardiomiopatía Dilatada/genética , Cardiomiopatía Dilatada/terapia , Perfilación de la Expresión Génica , Genoma Humano/genética , Adiponectina/genética , Adiponectina/metabolismo , Adulto , Anciano , Proteína 61 Rica en Cisteína , Citocinas/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Redes Reguladoras de Genes , Humanos , Proteínas Inmediatas-Precoces/genética , Proteínas Inmediatas-Precoces/metabolismo , Péptidos y Proteínas de Señalización Intercelular/genética , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Persona de Mediana Edad , Modelos Biológicos , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/metabolismoRESUMEN
To evaluate the human herpes virus 6 (HHV-6) -specific immune response in individuals with chromosomally integrated HHV-6 (ciHHV-6), we measured HHV-6-antigen-specific cytokine responses (interferon-γ, interleukin-2, tumour necrosis factor-α) in T cells by flow cytometry in 12 and 16 individuals with and without ciHHV-6, respectively. All individuals with ciHHV-6 showed HHV-6-specific T cells with higher frequencies of HHV-6-specific CD8(+) cells (0.03-14.93, median 2.15% of CD8(+) cells) compared with non-ciHHV-6 (0.0-10.67, median 0.36%, p 0.026). The observed increased HHV-6-specific functionally active responses in individuals with ciHHV-6 clearly disprove speculations on immune tolerance in ciHHV-6 and indicate clinical and immunological implications of ciHHV-6.
Asunto(s)
Citocinas/metabolismo , Herpesvirus Humano 6/genética , Infecciones por Roseolovirus/virología , Linfocitos T/citología , Adulto , Anciano , Anciano de 80 o más Años , Cromosomas Humanos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Roseolovirus/genética , Infecciones por Roseolovirus/inmunología , Linfocitos T/metabolismo , Integración Viral , Adulto JovenRESUMEN
BACKGROUND: Human herpesvirus 6 (HHV-6) A and B are lymphotropic viruses with life-long persistence, primarily associated with non-cardiac diseases, and discussed as a possible etiologic factor of myocarditis and cardiomyopathy. OBJECTIVE: To analyze the long-term spontaneous course of cardiac patients suffering from suspected inflammatory cardiomyopathy (CMi) with persisting HHV-6 A and B infections by follow-up biopsies. STUDY DESIGN: We prospectively evaluated patients (n=73) with biopsy-proven viral HHV-6 A and B infection in endomyocardial biopsies (EMBs), followed up by reanalysis of EMBs and left ventricular ejection fraction (LV-EF) measurements after a median period of 8.8 months (range 4-73 months). Beyond, we studied HHV-6 prevalence in isolated peripheral blood cells (PBCs) and HHV-6 species in EMBs. HHV-6 species-specific cellular infection sites within the myocardium were identified by immunohistochemistry (IHC). RESULTS: We identified 73 patients with cardiac HHV-6 A and B persistence or newly detected in follow-up EMB (95.0% B). Proof of HHV-6 in PBCs was primarily associated with A. Persistence of cardiac HHV-6 B genome was significantly associated with cardiac dysfunction at follow-up (LV-EF deteriorated from 58.2±16.0 to 51.8±17.2%, p<0.001), and LV improvement was observed when HHV-6 B persistence resolved (LV-EF increased from 54.9±15.4 to 60.7±13.1%, p<0.001). CONCLUSIONS: Persistence of cardiac HHV-6 B genomes was significantly associated with cardiac dysfunction, and hemodynamic parameters improved in association with HHV-6 B clearance.
Asunto(s)
Biopsia , Cardiomiopatías/patología , Cardiomiopatías/virología , Corazón/virología , Herpesvirus Humano 6/aislamiento & purificación , Infecciones por Roseolovirus/complicaciones , Disfunción Ventricular Izquierda/fisiopatología , Adulto , Anciano , Sangre/virología , Femenino , Herpesvirus Humano 6/clasificación , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Miocardio/patología , Estudios Prospectivos , Infecciones por Roseolovirus/virologíaRESUMEN
OBJECTIVE: The purpose of the current study was to characterize the effect of chimeric AS-ODNs encapsulated with cationic lipids on MDR in human leukemia cells and to determine if this modification of the ODN alone or in combination with the cationic lipid might offer advantages over classical ODN treatment with free unmodulated or phosphorothiolated AS-ODNs. Furthermore, we extended the antisense method to the use of AS-ODNs in the parental drug-sensitive leukemia cells which express mdr1-mRNA at a relative low level and lack P170 expression to evaluate the effectiveness of prophylactic AS-ODN treatment. METHODS: The effect of a 4-day AS-ODN treatment in drug-resistant human leukemia cells which exhibit the classic MDR phenotype at a moderate level was examined. Twenty-four hours after the last ODN administration the cells were analyzed for mdr1-mRNA (quantitative RT-PCR) and P170 expression (FCM), for R123 accumulation/efflux capacity (FCM) and for sensitivity to vincristine (MTT). In the parental drug-sensitive CCRF-CEM cells the mdr1-mRNA expression was assessed 24, 48 and 72 h after AS-ODN treatment administered as free phosphorothioate or conjugated with DMRIE-C. RESULTS: Cationic lipids produced a clear increase in cellular ODN uptake but also caused an increase in variability of uptake rates (30% vs. 10% variability after free phosphorothioates). Both AS-ODNs inhibit P170 expression whereby the antisense effect of the chimeric ODN seems to be stronger compared to the phosphorothioate (30% vs. 22% MRK16 staining). Consistent with the inhibition of P170 expression, an increased sensitivity to vincristine was observed. In parental drug-sensitive cells, AS-ODN treatment caused nearly complete inhibition of mdr1-mRNA expression (5% of control). CONCLUSION: The data demonstrate that it is nearly impossible to achieve a complete reversal of the MDR phenotype in drug-resistant cells using AS-ODNs. A more promising approach seems to be the prophylactic treatment with AS-ODNs.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Resistencia a Múltiples Medicamentos , Leucemia Linfoide/tratamiento farmacológico , Oligonucleótidos Antisentido/farmacología , ARN Mensajero/efectos de los fármacos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/efectos de los fármacos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Cartilla de ADN , Esquema de Medicación , Resistencia a Antineoplásicos , Regulación Neoplásica de la Expresión Génica , Genes MDR/efectos de los fármacos , Humanos , Oligonucleótidos Antisentido/administración & dosificación , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
Mononuclear cells prepared from peripheral blood or bone marrow of 119 AML and 28 ALL patients prior and following therapy were analyzed for absolute transcript levels of the chemoresistance genes mdr-1 and MRP, and the proto-oncogene bcl-2, by validated contamination-protected quantitative RT-PCR. In newly diagnosed AML mainly tumors of the granulocytic lineage (FAB M1-M2) expressed increased mdr-1 mRNA amounts. The MRP gene was expressed in all investigated samples without relation to a particular FAB class. High initial expression of both genes did not confer a poor prognosis even at high number of CD34+ cells. Data compared prior to and after therapy start (paired samples) revealed that AML patients who did not respond to therapy (NR) expressed increased levels of mdr-1 mRNA, as well as MRP and bcl-2 cDNA normalized to GAPDH reference transcripts, when compared to patients achieving complete remission (CR; p = 0.003, 0.008 and 0.0005, respectively). In ALL-NR the mdr-1 and bcl-2 genes were entirely more active after induction chemotherapy. Arbitrary cut-off values were established in order to delimit pathological from non-pathological gene expression. 59% of studied AML and 33% of ALL-NR exceeded the arbitrary values (mdr-1: > 2 amol/microgram RNA, MRP: > 10 zmol/amol GAPDH, bcl-2: > 5 zmol/amol GAPDH) for one and 11% of AML-NR for two parameters. Only 17% of the AML-CR and none of the ALL-CR group were above these limits. The results indicate that high individual activity of usually one, rarely two of the investigated genes might be associated with poor clinical outcome in treated acute leukemia.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Transportadoras de Casetes de Unión a ATP/genética , Resistencia a Múltiples Medicamentos/genética , Leucemia Mieloide Aguda/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Proteínas Proto-Oncogénicas c-bcl-2/genética , Transcripción Genética , Crisis Blástica , Células de la Médula Ósea/patología , Genes MDR , Genes bcl-2 , Humanos , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/patología , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , Reacción en Cadena de la Polimerasa , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangre , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Proto-Oncogenes Mas , ARN Mensajero/genética , Inducción de Remisión , Reproducibilidad de los Resultados , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodosAsunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Resistencia a Múltiples Medicamentos , Oligonucleótidos Antisentido/farmacología , Tionucleótidos/farmacología , Transportadoras de Casetes de Unión a ATP/biosíntesis , Antibióticos Antineoplásicos/farmacología , División Celular/efectos de los fármacos , Doxorrubicina/farmacología , Humanos , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , ARN Mensajero/biosíntesis , Células Tumorales Cultivadas/efectos de los fármacosAsunto(s)
Resistencia a Múltiples Medicamentos , Leucemia Mieloide Aguda/tratamiento farmacológico , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/análisis , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Transportadoras de Casetes de Unión a ATP/análisis , Transportadoras de Casetes de Unión a ATP/genética , Antígenos CD34/análisis , Antígenos CD34/genética , Apoptosis/efectos de los fármacos , Supervivencia Celular , Estudios de Cohortes , Alemania , Humanos , Inmunohistoquímica , Monocitos/metabolismo , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , Proteínas de Neoplasias/análisis , Proteínas de Neoplasias/genética , Fenotipo , Reacción en Cadena de la Polimerasa , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Proteínas Proto-Oncogénicas c-bcl-2/genética , ARN Mensajero/análisis , ARN Mensajero/genéticaRESUMEN
Distinct examinations and resulting therapies are depending on the cardiomyopathy phenotype and the severity of the myocardial compromise. Specific treatment modalities for distinct cardiomyopathies, demand detailed diagnostic procedures in addition to the routine diagnostic workup. Quality analyses for causal treatment strategies of different cardiomyopathies are missing. Most diagnostic procedures are unable to detect the relevant pathophysiological changes that generally occur at the cellular and molecular level of myocardial tissue or individual cells. Therefore, often only additional biopsy-based tissue analyses can provide the necessary basis for causal treatment options.
Asunto(s)
Cardiomiopatías/terapia , Biopsia , Cardiomegalia/terapia , Cardiomiopatías/clasificación , Cardiomiopatías/genética , Cardiomiopatías/patología , Cardiomiopatía Restrictiva/clasificación , Cardiomiopatía Restrictiva/genética , Cardiomiopatía Restrictiva/patología , Cardiomiopatía Restrictiva/terapia , Diagnóstico Diferencial , Electrocardiografía/métodos , Cardiopatías/terapia , Humanos , Mutación , Contracción Miocárdica , Miocardio/patología , Pronóstico , Garantía de la Calidad de Atención de SaludAsunto(s)
Vasos Coronarios/patología , Células Gigantes/patología , Miocarditis/patología , Miocardio/patología , Adulto , Biomarcadores/análisis , Biopsia , Estudios de Casos y Controles , Vasos Coronarios/inmunología , Femenino , Regulación de la Expresión Génica , Células Gigantes/inmunología , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Miocarditis/genética , Miocarditis/inmunología , Miocarditis/fisiopatología , Miocardio/inmunología , ARN Mensajero/análisis , Volumen Sistólico , Función Ventricular IzquierdaRESUMEN
Parvovirus B19 (PVB19) is a member of the human erythrovirus family detected frequently in endomyocardial biopsies from patients with dilated cardiomyopathy. Human erythroviruses cluster into three genotypes 1-3 which share a high degree of homology between major structural proteins and may cause indistinguishable infections clinically and serologically. In human cardiac tissue erythrovirus genotypes other than PVB19 have not yet been reported. Three hundred seventeen consecutive patients with symptomatic dilated cardiomyopathy (median left ventricular ejection fraction: 28.6%, range 5-45%) who underwent endomyocardial biopsy for the elucidation of the etiology, were analyzed using a new consensus PCR assay designed for the detection of the three erythrovirus genotype sequences. Endomyocardial biopsies of 151 (47.6%) patients were erythrovirus-positive. Genotype 1 specific sequences were detected in 43/151 (28.5%) of positive biopsy samples, whereas genotype 2-specific sequences so far considered rare in human disease and not yet been described in human heart tissue was identified in 108/151 (71.5%) of virus-positive endomyocardial biopsies with a preference in patients above 50 years of age. In spite of younger age, systolic left ventricular dysfunction of genotype 1-positive patients was significantly reduced as compared to genotype 2-positive patients (24.4+/-10.4% vs. 31.0+/-9.5%, P=0.0001) at the initial presentation. The data show that two genetically distinct erythrovirus variants with a different age distribution are detectable in endomyocardial biopsies of patients with dilated cardiomyopathy. The erythrovirus genotype 2, not described previously in human heart tissue, is highly prevalent in the heart but the less prevalent genotype 1 is associated with more severe disturbed cardiac function.
Asunto(s)
Cardiomiopatía Dilatada/virología , Erythrovirus/aislamiento & purificación , Corazón/virología , Infecciones por Parvoviridae/virología , Adulto , Anciano , Secuencia de Aminoácidos , Secuencia de Bases , Proteínas de la Cápside/química , Erythrovirus/genética , Femenino , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Prevalencia , Alineación de Secuencia , Carga ViralAsunto(s)
Antivirales/administración & dosificación , Cardiomiopatía Dilatada/tratamiento farmacológico , Infecciones por Enterovirus/tratamiento farmacológico , Enterovirus/aislamiento & purificación , Interferón beta/administración & dosificación , Adulto , Antivirales/sangre , Biopsia , Cardiomiopatía Dilatada/mortalidad , Cardiomiopatía Dilatada/virología , Estudios de Cohortes , Infecciones por Enterovirus/mortalidad , Infecciones por Enterovirus/virología , Femenino , Estudios de Seguimiento , Humanos , Interferón beta/sangre , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
The role of endomyocardial biopsies in patients with clinically suspected acute myocarditis, myocarditis in the past, and dilated cardiomyopathy is discussed controversially. In fact, it is still under discussion whether information obtained from endomyocardial biopsies is relevant for further clinical decisions. Therefore this Critical Perspective will deal with the question, which patient should undergo endomyocardial biopsy investigations for an etiopathogenic differentiation of the disease and for the possible choice of immunomodulatory treatment strategies.